Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and Bioavailability of LY4065967 in Healthy Men
NCT07039045Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LY4065967 (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Total Radioactive Dose in Urine and Fecal Excretion at 21 days and Plasma Area Under the Concentration-time Curve from Zero to Infinity (AUC(0-inf)) for LY4065967 at 9 days. Started Jun 2025; status: completed.
02
Drugs
LY4065967
Beyond the preview
Go deeper on NCT07039045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07039045.